These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 16842393)

  • 1. Poor correlation between 6beta-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity.
    Chen YC; Gotzkowsky SK; Nafziger AN; Kulawy RW; Rocci ML; Bertino JS; Kashuba AD
    Br J Clin Pharmacol; 2006 Aug; 62(2):187-95. PubMed ID: 16842393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary 6β-Hydroxycortisol/Cortisol Ratio Most Highly Correlates With Midazolam Clearance Under Hepatic CYP3A Inhibition and Induction in Females: A Pharmacometabolomics Approach.
    Shin KH; Ahn LY; Choi MH; Moon JY; Lee J; Jang IJ; Yu KS; Cho JY
    AAPS J; 2016 Sep; 18(5):1254-1261. PubMed ID: 27317471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese.
    Chan SW; Xiao Y; Hu M; Yin OQ; Chu TT; Fok BS; Lee VH; Tomlinson B
    J Clin Pharm Ther; 2016 Oct; 41(5):552-8. PubMed ID: 27511886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poor correlation between 6beta-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity: a comment.
    Fenske M
    Br J Clin Pharmacol; 2007 May; 63(5):632; author reply 633. PubMed ID: 17094779
    [No Abstract]   [Full Text] [Related]  

  • 5. Midazolam and cortisol metabolism before and after CYP3A induction in humans.
    Eeckhoudt SL; Desager JP; Robert AR; Leclercq I; Verbeeck RK; Horsmans Y
    Int J Clin Pharmacol Ther; 2001 Jul; 39(7):293-9. PubMed ID: 11471773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the Selective Orexin-1 Receptor Antagonist ACT-539313 on the Pharmacokinetics of the CYP3A Probe Drug Midazolam in Healthy Male Subjects.
    Berger B; Kaufmann P; Koch A; Dingemanse J
    J Clin Pharmacol; 2020 Jul; 60(7):931-941. PubMed ID: 32035014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol.
    Ushiama H; Echizen H; Nachi S; Ohnishi A
    Clin Pharmacol Ther; 2002 Jul; 72(1):33-43. PubMed ID: 12152002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects.
    Woolsey SJ; Beaton MD; Choi YH; Dresser GK; Gryn SE; Kim RB; Tirona RG
    Basic Clin Pharmacol Toxicol; 2016 Apr; 118(4):284-91. PubMed ID: 26399557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quinine compared to 4β-hydroxycholesterol and midazolam as markers for CYP3A induction by rifampicin.
    Björkhem-Bergman L; Bäckström T; Nylén H; Rönquist-Nii Y; Bredberg E; Andersson TB; Bertilsson L; Diczfalusy U
    Drug Metab Pharmacokinet; 2014; 29(4):352-5. PubMed ID: 24522201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of midazolam urinary metabolic ratios for cytochrome P450 3A (CYP3A) phenotyping.
    Streetman DS; Kashuba AD; Bertino JS; Kulawy R; Rocci ML; Nafziger AN
    Pharmacogenetics; 2001 Jun; 11(4):349-55. PubMed ID: 11434513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary metabolic markers reflect on hepatic, not intestinal, CYP3A activity in healthy subjects.
    Lee S; Lee Y; Kim AH; Yoon S; Lee J; Ji SC; Yoon SH; Lee S; Yu KS; Jang IJ; Cho JY
    Drug Metab Pharmacokinet; 2021 Feb; 36():100374. PubMed ID: 33348239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of CYP3A activity in humans using three different parameters based on endogenous cortisol metabolism.
    Luo X; Li XM; Hu ZY; Cheng ZN
    Acta Pharmacol Sin; 2009 Sep; 30(9):1323-9. PubMed ID: 19701237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interindividual and intraindividual variability of the urinary 6beta-Hydroxycortisol/Cortisol ratio in Chinese subjects: implications of its use for evaluating CYP3A activity.
    Yin OQ; Shi X; Tomlinson B; Chow MS
    J Clin Pharmacol; 2004 Dec; 44(12):1412-7. PubMed ID: 15545313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circadian variation of the urinary 6beta-hydroxycortisol to cortisol ratio that would reflect hepatic CYP3A activity.
    Ohno M; Yamaguchi I; Ito T; Saiki K; Yamamoto I; Azuma J
    Eur J Clin Pharmacol; 2000; 55(11-12):861-5. PubMed ID: 10805065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for the validity of cortisol 6 beta-hydroxylation clearance as a new index for in vivo cytochrome P450 3A phenotyping in humans.
    Furuta T; Suzuki A; Mori C; Shibasaki H; Yokokawa A; Kasuya Y
    Drug Metab Dispos; 2003 Nov; 31(11):1283-7. PubMed ID: 14570755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraindividual and interindividual variabilities in endogenous cortisol 6β-hydroxylation clearance as an index for in vivo CYP3A phenotyping in humans.
    Shibasaki H; Hosoda K; Goto M; Suzuki A; Yokokawa A; Ishii K; Furuta T
    Drug Metab Dispos; 2013 Feb; 41(2):475-9. PubMed ID: 23175666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A.
    Kinirons MT; O'Shea D; Kim RB; Groopman JD; Thummel KE; Wood AJ; Wilkinson GR
    Clin Pharmacol Ther; 1999 Sep; 66(3):224-31. PubMed ID: 10511057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects.
    Kasichayanula S; Boulton DW; Luo WL; Rodrigues AD; Yang Z; Goodenough A; Lee M; Jemal M; LaCreta F
    Br J Clin Pharmacol; 2014 Nov; 78(5):1122-34. PubMed ID: 24837659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative prediction of hepatic CYP3A activity using endogenous markers in healthy subjects after administration of CYP3A inhibitors or inducers.
    Lee J; Yoon SH; Yi S; Kim AH; Kim B; Lee S; Yu KS; Jang IJ; Cho JY
    Drug Metab Pharmacokinet; 2019 Aug; 34(4):247-252. PubMed ID: 31088714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increase in urinary excretion of 6beta-hydroxycortisol in common marmosets as a marker of hepatic CYP3A induction.
    Totsuka S; Watanabe T; Koyanagi F; Tanaka K; Yasuda M; Manabe S
    Arch Toxicol; 1999; 73(4-5):203-7. PubMed ID: 10463384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.